Navigation Links
Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID
Date:12/17/2008

Experts assess likelihood of use to treat mildly infected diabetic foot ulcers based upon data from randomized, controlled, double-blinded multi-center clinical trials of pexiganan cream

DALLAS, Dec. 17 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and MACROCHEM CORPORATION (OTC Bulletin Board: MACM) announced today that the results of two Phase 3 studies of pexiganan for the topical treatment of mild diabetic foot infection were published in the December 15, 2008 issue of Clinical Infectious Diseases. The publication was authored by Benjamin A. Lipsky, M.D., Veteran's Affairs Puget Sound Healthcare System and the University of Washington School of Medicine, Seattle, WA; Kenneth J. Holroyd, M.D., Vanderbilt University School of Medicine, Nashville, TN; and Michael Zasloff, M.D., Georgetown University School of Medicine, Washington, D.C. The authors concluded that based on the data from these Phase 3 studies, topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria.

Overall, 835 patients were randomized; those in each treatment arm were similar with regard to dermographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patie
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
2. CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure
3. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
4. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
5. Promising trials of malaria vaccine lead to calls for Phase 3 development
6. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
7. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
8. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
9. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
10. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
11. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... The ... 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She is recognized ... over 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for ...
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published ... side of plastic surgery and explained why people should not shy away from their ... the excesses of the few and celebrate it for the modern wonder that it ...
(Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just recently performed ... patient is high-end athlete, whose accomplishments include running in 27 triathlons and swimming the ... which was diagnosed as tendinitis. I did an ultrasound and found a partial ...
(Date:7/27/2015)... ... July 27, 2015 , ... Send Word Now, ... mobile collaboration, announced today the latest software release for its award-winning ... feature enhancements. , This software release gives the widely used online application a ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2
... for out-of-hospital cardiac arrest, an analysis of data indicates their ... in an improved rate of survival, according to a study ... study is being released early online because it will be ... of automated external defibrillators (AEDs) has been proposed as a ...
... blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using ... heart failure or cardiovascular death in older adults, according to ... of JAMA . The study is being released early ... Association,s annual meeting. "Older adults comprise the majority of ...
... be caused by the gradual accumulation in the brain of amyloid-beta ... formed from a protein known as APP, which is found in ... study for the disease does not distinguish between the different ... Journal of Biological Chemistry , show that amyloid beta peptide is ...
... (HealthDay News) -- Could cholesterol deposits on or around ... preliminary Danish study suggests that the deposits could point ... and early death. Half of patients with such ... cholesterol levels. The research team therefore believes that buildup ...
... Reporter , MONDAY, Nov. 15 (HealthDay News) -- Omega-3 fatty ... a type of irregular heartbeat that can cause stroke, new ... don,t work for most patients with AF [atrial fibrillation]," said ... in the Dec. 1 issue of the Journal of ...
... News) -- As children mature, increased synchronization between specific ... and others, a new study suggests. This includes ... University Medical Center researchers used functional MRI to examine ... comprise what,s known as the default-mode network (DMN). ...
Cached Medicine News:Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 2Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 3Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 2Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Cholesterol on Eyelids Might Point to Heart Risk 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 3Health News:Brain Organizes Itself for Introspection as Children Age: Study 2
(Date:7/27/2015)... 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ) today ... modality products. This approval allows the company to sell these products ... the world. "Receiving the CE Mark represents the achievement ... Kelvyn H. Cullimore Jr. , president and CEO of Dynatronics. "Over ... China , Japan , ...
(Date:7/27/2015)... 27, 2015 According to the ... Study (2014-2019) by Type (DNA ISH, RNA ISH), By ... User (Hospitals, Pharma & Biotech Companies, Research Labs, CROs)", ... million 2014 and is estimated to reach $681.0 million ... forecast period, 2014 to 2019. Browse through ...
(Date:7/27/2015)... CITY, Calif. , July 27, 2015  Cardica, Inc. ... financial results for its fiscal fourth quarter ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call ... 2015, at 4:30 p.m. Eastern Time via phone, please dial ...
Breaking Medicine Technology:Dynatronics Awarded CE Mark Approval for Its Solaris Products 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... 22, 2010 Delcath Systems, Inc. (Nasdaq: ... the remaining modules of its 505(b)(2) New Drug Application ... Food & Drug Administration (FDA). The Company had previously ... to the FDA in late April 2010. The Company ...
... 22, 2010 Edge EHR Corp., EDGE, a ... OS®, is pleased to announce the release of ... offices looking to leverage the awesome power of the ... (Logo:   http://photos.prnewswire.com/prnh/20100310/AQ68604LOGO ) ...
Cached Medicine Technology:Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System 2Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System 3Edge EHR Corp. Announces edgeDMS for iPad, Native Touch-Based Clinical Charting Software for the Paperless Dental Office. 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: